CA Patent

CA2456281A1 — Pyrane derivatives as both ace- and nep- inhibitors

Assigned to Novartis AG · Expires 2003-04-03 · 23y expired

What this patent protects

Compounds of the formula (I), wherein R1, R1-R7 and alk have meaning as defined, pharmaceutical compositions thereof, and use thereof for the treatment and/or prevention of cardiovascular disorders responsive to ACE and NEP inhibition and/or ECE inhibition.

USPTO Abstract

Compounds of the formula (I), wherein R1, R1-R7 and alk have meaning as defined, pharmaceutical compositions thereof, and use thereof for the treatment and/or prevention of cardiovascular disorders responsive to ACE and NEP inhibition and/or ECE inhibition.

Drugs covered by this patent

Patent Metadata

Patent number
CA2456281A1
Jurisdiction
CA
Classification
—
Expires
2003-04-03
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.